<PAPER><mode2 name='PMC4342006' hasDoc='yes' version='597'></mode2><article xmlns:mml='http://www.w3.org/1998/Math/MathML' xmlns:xlink='http://www.w3.org/1999/xlink' article-type='research-article'><front><journal-meta><journal-id journal-id-type='nlm-ta'>Alzheimers Res Ther</journal-id><journal-id journal-id-type='iso-abbrev'>Alzheimers Res Ther</journal-id><journal-title-group><journal-title>Alzheimer's Research &amp; Therapy</journal-title></journal-title-group><issn pub-type='epub'>1758-9193</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type='pmcid'>4342006</article-id><article-id pub-id-type='publisher-id'>104</article-id><article-id pub-id-type='doi'>10.1186/s13195-015-0104-7</article-id><article-categories><subj-group subj-group-type='heading'><subject>Review</subject></subj-group></article-categories><title-group><article-title><s sid='1'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>Clinical and imaging features of mixed Alzheimer and vascular pathologies</s></article-title></title-group><contrib-group><contrib contrib-type='author' corresp='yes'><name><surname>Chui</surname><given-names>Helena C</given-names></name><address><email>chui@usc.edu</email></address><xref rid='Aff1' ref-type='aff'></xref></contrib><contrib contrib-type='author'><name><surname>Ramirez-Gomez</surname><given-names>Liliana</given-names></name><address><email>liliana.ramirezgomez@med.usc.edu</email></address><xref rid='Aff1' ref-type='aff'></xref></contrib><aff id='Aff1'>Department of Neurology, University of Southern California, 1570 Alcazar Street, Suite 215, Los Angeles, CA 90033 USA </aff></contrib-group><pub-date pub-type='epub'><day>27</day><month>2</month><year>2015</year></pub-date><pub-date pub-type='pmc-release'><day>27</day><month>2</month><year>2015</year></pub-date><pub-date pub-type='collection'><year>2015</year></pub-date><volume>7</volume><issue>1</issue><elocation-id>21</elocation-id><permissions><copyright-statement>© Chui and Ramirez-Gomez; licensee BioMed Central. 2015</copyright-statement><license license-type='open-access'><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/licenses/by/4.0'>http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type='uri' xlink:href='http://creativecommons.org/publicdomain/zero/1.0/'>http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id='Abs1'><p><s sid='2'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The co-occurrence of both Alzheimer disease (AD) pathology and vascular brain injury (VBI) is very common, especially amongst the oldest of old.</s><s sid='3'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In neuropathologic studies, the prevalence of AD, VBI, and mixed AD/VBI lesions ranks ahead of Lewy bodies and hippocampal sclerosis.</s><s sid='4'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> In the modern era of structural magnetic resonance imaging (MRI) and amyloid positron emission tomography (PET) imaging, this review examines 1) the prevalence of mixed AD and VBI pathology, 2) the significance of these pathologies for cognitive impairment (AD and vascular cognitive impairment (VCI)), and 3) the diagnosis and treatment of mixed AD/VCI.</s><s sid='5'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Although epidemiologic studies report that vascular risk factors for arteriosclerosis increase the risk of incident AD, both autopsy and amyloid PET studies indicate that AD and VBI contribute additively, but independently, to the risk of dementia.</s><s sid='6'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The literature confirms the malignancy of AD and highlights the adverse effects of microinfarcts on cognitive function.</s><s sid='7'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For the clinical diagnosis of mixed AD/VCI, the presence of AD can be recognized by neuropsychological profile, structural imaging, cerebrospinal fluid biomarkers, and glucose PET and amyloid PET imaging.</s><s sid='8'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The diagnosis of VBI, however, still hinges predominantly on the structural MRI findings.</s><s sid='9'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Severe amnesia and atrophy of the hippocampus are characteristic of early AD, whereas the cognitive profile for VCI is highly variable and dependent on size and location of VBI.</s><s sid='10'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The cognitive profile of mixed AD/VBI is dominated by AD.</s><s sid='11'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> With the notable exception of microinfarcts (which elude <italic>in vivo</italic> detection), infarcts, hemorrhages, and white matter hyperintensities on structural MRI currently represent the best markers for the presence VBI.</s><s sid='12'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Better markers that reflect the health and reactivity of intracerebral blood vessels are needed.</s><s sid='13'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> For prevention and treatment, the type of underlying cerebrovascular disease (for example, arteriosclerosis or cerebral amyloid angiopathy) should be considered.</s><s sid='14'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> It is likely that reduction of vascular risk factors for arteriosclerosis can significantly reduce vascular contributions to mixed dementia.</s></p></abstract><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type='intro' id='Sec1'><title>Introduction</title><p><s sid='15'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Traditionally, Alzheimer disease (AD) and vascular dementia are recognized as the two most prevalent forms of dementia in late life.</s><s sid='16'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A combination of AD and vascular pathologies (so-called mixed dementia) is usually registered as a close third, moving up to first or second in rank in community-based studies of the oldest of old.</s><s sid='17'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Conceptualization and diagnosis of these entities has been evolving from clinical-pathological phenotypes, which could not be resolved until autopsy, to new research diagnostic criteria that incorporate molecular biomarkers (for example, amyloid-beta (Aβ) and phosphorylated tau), and <italic>in vivo</italic> structural, functional, and perfusion imaging.</s><s sid='18'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Neuropsychological features (for example, pattern and severity of impairment across principle cognitive domains) remain relevant to diagnosis and clinical care.</s><s sid='19'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Innovations are underway in computerized neuropsychological assessment (for example, computerized assessment with continuous measures, such as the National Institutes of Health tool box) and rethinking cognitive impairment in terms of functional neural networks.</s><s sid='20'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1> In this review, we consider mainly how recent advances in biomarkers and imaging have altered our conceptualization and diagnosis of mixed AD and vascular pathologies.</s></p><p><s sid='21'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Medically speaking, the approach to mixed AD and vascular pathologies should be tied to prevention and treatment.</s><s sid='22'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> During the past 30 years, emphasis has moved from dementia to mild cognitive impairment to preclinical disease, in the hopes that prevention and treatment can be instituted earlier in the disease course.</s><s sid='23'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> AD is currently conceptualized as a combined amyloidopathy and tau-related neurodegeneration.</s><s sid='24'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Mainstream strategies to prevent and treat AD target these misfolded proteins.</s></p><p><s sid='25'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mod1' type='Mod'></CoreSc1>The model for vascular cognitive impairment (VCI) adopted here posits that vascular risk factors (VRFs) lead to cerebrovascular disease (CVD), which leads to vascular brain injury (VBI), which leads to VCI (Figure <xref rid='Fig1' ref-type='fig'>1</xref>).</s><s sid='26'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It is paramount to maintain focus on the type of CVD (the cause), as well as on the resulting VBI and VCI.</s><s sid='27'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> For example, the prevention and treatment of cerebral amyloid angiopathy (CAA), which is intrinsically associated with AD, is likely to differ fundamentally from the prevention and treatment of atherosclerosis.</s><s sid='28'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> It may pay off to pay some attention to terminology, rather than to lump all vascular dementias into the category of VCI.<fig id='Fig1'><label>Figure 1</label><caption><p><bold>Mixed Alzheimer disease/vascular brain injury.</bold> Additive parallel or interactive pathways? AD, Alzheimer disease; ApoE, apolipoprotein E; CAA, cerebral amyloid angiopathy; CSF, cerebrospinal fluid; CVD, cerebrovascular disease; MRI, magnetic resonance imaging; PET, positron emission tomography; VBI, vascular brain injury; VCI, vascular cognitive impairment; VRF, vascular risk factor; WMH, white matter hyperintensity.</p></caption><graphic id='MO1' xlink:href='13195_2015_104_Fig1_HTML'></graphic></fig></s></p><p><s sid='29'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Goa1' type='Goa'></CoreSc1>In this review of clinical and imaging features of mixed AD/VCI, we have chosen nuanced terminology to distinguish levels of vascular factors: mixed AD/VRFs, mixed AD/CVD, mixed AD/VBI, and mixed AD/VCI.</s><s sid='30'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> We use the term VCI when clinical criteria are used to define groups, VBI when study groups are defined by infarcts/hemorrhages noted by imaging/pathology, and CVD to refer to specific disorders of blood vessels (for example, atherosclerosis or amyloid angiopathy).</s><s sid='31'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Finally, we use the term VRFs to refer to traditional risk factors for atherosclerosis (for example, hypertension, diabetes mellitus, and hyperlipidemia) and not for amyloid angiopathy (for example, apolipoprotein E (ApoE) ε4 is mentioned distinctly and not included under the label VRF in this review).</s></p><p><s sid='32'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The diagnosis of VCI is reflected in recent clinical criteria [<xref rid='CR1' ref-type='bibr'>1</xref>], which draw heavily on evidence of infarcts, white matter hyperintensities (WMHs) and microbleeds (MBs) using structural magnetic resonance imaging (MRI).</s><s sid='33'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Multiple autopsy studies have shown that microinfarcts (one type of VBI) are major risk factors for VCI; however, microinfarcts fall below the resolution of 1.5 and 3 T MRI.</s><s sid='34'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> This is one of several gaps in <italic>in vivo</italic> detection that we must close going forward.</s></p><p><s sid='35'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>For the diagnosis of AD in this review, we adopt research-level criteria for high likelihood of preclinical, mild cognitive impairment and dementia due to AD based on biomarker evidence [<xref rid='CR2' ref-type='bibr'>2</xref>-<xref rid='CR4' ref-type='bibr'>4</xref>].</s><s sid='36'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> This requires evidence of 1) amyloid deposition by autopsy, low cerebrospinal fluid (CSF) Aβ, or positive amyloid positron emission tomography (PET) and 2) neurodegeneration by autopsy, high CSF ptau, and AD pattern of atrophy on structural imaging.</s><s sid='37'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> While amyloid and tau biomarkers are not required in clinical practice for the diagnosis of AD, this review is intentionally more selective.</s></p><p><s sid='38'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In attempting to define clinical and imaging features of entities that are defined by clinical and imaging phenotype, we must be aware of possible circular reasoning.</s><s sid='39'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> For example, in seeking to characterize neuropsychological features, we have selected study groups based on mixed AD/VBI, not mixed AD/VCI (unless the diagnosis of VCI was reached without knowledge of the neuropsychological profile).</s></p><p><s sid='40'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>Diagnostic classifications such as AD, VCI and mixed AD/VCI represent an oversimplified dichotomous framework, necessary for clinical practice.</s><s sid='41'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> With the expanding repertoire of neuroimaging modalities, it makes sense in the long term to adopt a multi-factorial model that plugs in continuous measures of AD and VBI as independent variables and looks to continuous measures of various cognitive domains as the outcome.</s><s sid='42'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Indeed, many of the studies reviewed below used multi-factorial models where imaging features are correlated with cognitive performance.</s></p><p><s sid='43'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>We are now at the infancy of testing whether these cognitive outcomes are mediated by injury to corresponding cognitive networks (using functional MRI and diffuse tensor imaging) and how these systems change over time.</s><s sid='44'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> We look forward to visualizing how AD pathology and VBI impact neural networks and how treatment might protect, sustain, and repair them.</s></p></sec><sec id='Sec2'><title>Prevalence of mixed AD/VCI or mixed AD/VBI in prospective longitudinal autopsy studies</title><p><s sid='45'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Over four decades ago, the high prevalence of AD and vascular pathology in older patients (mean age = 76.4 years) was brought to light by Tomlinson, Blessed, and Roth [<xref rid='CR5' ref-type='bibr'>5</xref>,<xref rid='CR6' ref-type='bibr'>6</xref>].</s><s sid='46'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Previously, AD had been considered a relatively rare cause of early onset dementia, while arteriosclerosis was widely held to be the most common cause of late onset dementia.</s><s sid='47'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Among 50 cases with dementia living in a mental hospital, widespread plaques and tangles (that is, AD changes) were the predominant pathological lesions in 50%, while cerebral softening (that is, territorial infarcts) due to atherosclerosis accounted for 12 to 17%, and mixed AD and VBI pathologies were found in 8 to 18%.</s><s sid='48'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> At this juncture, the pendulum of clinical diagnosis and investigation swung dramatically from arteriosclerotic dementia to AD.</s></p><p><s sid='49'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In 1997, three decades later, the Nun Study heightened interest in mixed dementia, by showing additive effects of AD and VBI on risk of dementia [<xref rid='CR7' ref-type='bibr'>7</xref>].</s><s sid='50'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The Nun Study introduced a generation of prospective, longitudinal, clinic-to-autopsy cohort studies which have systematically addressed clinical-pathological correlations in dementia (Tables <xref rid='Tab1' ref-type='table'>1</xref> and <xref rid='Tab2' ref-type='table'>2</xref>).</s><s sid='51'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> We review some of these studies from the United States, United Kingdom, and Japan.</s><s sid='52'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The prevalence of mixed AD/VBI among cases with dementia ranges from 14 to 44%.</s><table-wrap id='Tab1'><label>Table 1</label><caption><p><bold>Community-based, autopsy studies are required to estimate the prevalence and incidence of mixed Alzheimer disease/vascular brain injury</bold></p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th><bold>Autopsy study</bold></th><th><bold>N</bold></th><th><bold>Mean age (years)</bold></th><th><bold>Diagnosis of AD</bold></th><th><bold>Diagnosis of VBI or VCI</bold></th><th><bold>Prevalence of mixed</bold></th><th><bold>Interaction between VBI and AD on risk of dementia</bold></th><th><bold>Neuropsychology</bold></th></tr></thead><tbody><tr valign='top'><td rowspan='2'>Nun Study [<xref rid='CR7' ref-type='bibr'>7</xref>]</td><td rowspan='2' align='left'>102</td><td rowspan='2' align='left'>87 (76-100)</td><td rowspan='2'>Khachaturian plaque criteria</td><td rowspan='2'>Number of infarcts &gt; or &lt;1.5 cm</td><td rowspan='2'>39% (24/61) of dementia cases were mixed</td><td rowspan='2'>Number of tangles and number of lacunes exert independent additive effect on MMSE and likelihood of dementia</td><td>MMSE</td></tr><tr valign='top'><td>CERAD</td></tr><tr valign='top'><td>ROS [<xref rid='CR8' ref-type='bibr'>8</xref>,<xref rid='CR9' ref-type='bibr'>9</xref>]</td><td align='left'>550</td><td align='left'>87</td><td>Mean number of neurofibrillary tangles, neuritic plaques, and diffuse plaques in five lobes</td><td>Number of macroscopic and microscopic infarcts</td><td>28% of dementia cases were mixed</td><td>AD and VBI pathology have additive effect on odds of dementia</td><td></td></tr><tr valign='top'><td>MAP [<xref rid='CR8' ref-type='bibr'>8</xref>,<xref rid='CR9' ref-type='bibr'>9</xref>]</td><td align='left'>425</td><td align='left'>87</td><td>Mean number of neurofibrillary tangles, neuritic plaques, and diffuse plaques in five lobes</td><td>Number of macroscopic and microscopic infarcts</td><td>44% of dementia cases were mixed</td><td></td><td></td></tr><tr valign='top'><td rowspan='2'>BLSA [<xref rid='CR10' ref-type='bibr'>10</xref>]</td><td rowspan='2' align='left'>179</td><td rowspan='4' align='left'>87.6 ± 7.1</td><td>CERAD</td><td>Macroscopic infarcts</td><td rowspan='2'>Hemispheral infarcts alone or with AD account for 35% of dementia cases</td><td rowspan='2'>In subjects with intermediate AD pathology scores, a single macroscopic hemispheral infarct was sufficient to cause dementia</td><td rowspan='4'>Blessed Memory Information Concentration Test</td></tr><tr valign='top'><td rowspan='3'>Braak and Braak stage</td><td>Microscopic infarcts</td></tr><tr valign='top'><td rowspan='2'>BLSA [<xref rid='CR11' ref-type='bibr'>11</xref>]</td><td align='left'>200</td><td rowspan='2'>Atherosclerosis (0-3) of coronary, aorta, and intracranial vessels</td><td rowspan='2'>45% have remote infarct</td><td rowspan='2'>68% of cases have atherosclerosis, which increased the odds of dementia independent of AD pathology or cerebral infarcts</td></tr><tr valign='top'><td>175 complete autopsies, including heart and aorta</td></tr><tr valign='top'><td rowspan='5'>MRC CFAS [<xref rid='CR12' ref-type='bibr'>12</xref>]</td><td>N = 456</td><td rowspan='7' align='left'>87 (SD = 7): range 66 to 100 (63% ≥85)</td><td>CERAD scale (0-3)</td><td rowspan='2'>Regional infarcts (&gt;1 cm)</td><td rowspan='5'></td><td rowspan='3'>Association between AD pathology and cognitive status goes down with age</td><td>MMSE</td></tr><tr valign='top'><td>243 dementia</td><td rowspan='6'>Diffuse plaques, neuritic plaques, tangles, atrophy</td><td rowspan='6'>AGECAT</td></tr><tr valign='top'><td rowspan='2'>183 without dementia</td><td rowspan='3'>Small vessel disease: lacunes, microinfarcts, white matter change</td></tr><tr valign='top'><td rowspan='2'>Association between atrophy and age continues to go up</td></tr><tr valign='top'><td rowspan='3'>30 unknown</td></tr><tr valign='top'><td rowspan='2'>MRC CFAS [<xref rid='CR13' ref-type='bibr'>13</xref>]</td><td>Self-reported vascular risk factors</td><td rowspan='2'></td><td rowspan='2'>Vascular risk factors were not associated with an increased burden of AD pathology at death in old age</td></tr><tr valign='top'><td>26% of non dementia cases had CVA; 43% of dementia cases had CVA</td></tr><tr valign='top'><td>CC75 + C [<xref rid='CR14' ref-type='bibr'>14</xref>]</td><td align='left'>224</td><td align='left'>91</td><td>CERAD</td><td></td><td>22% of 113 dementia cases</td><td></td><td></td></tr><tr valign='top'><td rowspan='3'>Hisayama [<xref rid='CR15' ref-type='bibr'>15</xref>]</td><td>N = 469</td><td rowspan='3'></td><td>CERAD</td><td rowspan='3'>NINDS-AIREN</td><td rowspan='3'>4.7% of dementia cases were mixed</td><td rowspan='3'></td><td rowspan='3'></td></tr><tr valign='top'><td>275 incident dementia cases</td><td rowspan='2'>NIA-Reagan</td></tr><tr valign='top'><td>(164 autopsies)</td></tr><tr valign='top'><td rowspan='2'>HAAS [<xref rid='CR16' ref-type='bibr'>16</xref>]</td><td rowspan='2'>N = 443</td><td align='left'>86 ± 5.2</td><td rowspan='2'>Mean number of neurofibrillary tangles and neuritic plaques over 20 fields in 4 lobes</td><td rowspan='2'>High correlations noted between MBIs and lacunar infarcts (Spearman r = 0.45, <italic>P</italic> &lt; 0.0001)</td><td rowspan='5'>14.2% of dementia cases were mixed</td><td rowspan='2'>No correlation between AD and microvascular lesions</td><td rowspan='5'>CASI</td></tr><tr valign='top'><td rowspan='4' align='left'>(72-90+)</td></tr><tr valign='top'><td rowspan='3'>HAAS [<xref rid='CR17' ref-type='bibr'>17</xref>]</td><td>N = 436</td><td rowspan='3'></td><td rowspan='3'>Number of infarcts &gt; or &lt;1.0 cm, microinfarcts</td><td rowspan='2'>MBI found in 72% of demented and 61% of non-demented</td></tr><tr valign='top'><td>144 with dementia</td></tr><tr valign='top'><td>292 without dementia</td><td>MBI and AD exert independent additive effects on cognition</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer disease; AGECAT, Automated Geriatric Examination for Computer Assisted Taxonomy; BLSA, Baltimore Longitudinal Aging Study; CASI, Cognitive Abilities Screening Instrument; CC75 + C, Cambridge City Over-75 s Cohort; CERAD, Consortium to Establish a Registry for Alzheimer Disease; CFAS, Cognitive Function and Ageing Study; CVA, cerebrovascular accident; HAAS, Honolulu Asia Aging Study; MAP, Rush Memory and Aging Project; MBI, microscopic brain infarct; MMSE, Mini-Mental State Exam; MRC, Medical Research Council; NIA, National Institute on Aging; NINDS-AIREN, National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; ROS, Rush Religious Order Study; SD, standard deviation; VBI, vascular brain injury; VCI, vascular cognitive impairment.</p></table-wrap-foot></table-wrap><table-wrap id='Tab2'><label>Table 2</label><caption><p><bold>Subcortical Ischemic Vascular Dementia (SIVD) Neuropathology study: imaging and clinical correlations</bold></p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th><bold>Autopsy study</bold></th><th><bold>N/pathological diagnosis</bold></th><th><bold>Mean age (years)</bold></th><th><bold>Diagnosis of AD</bold></th><th><bold>Diagnosis of VBI</bold></th><th><bold>Prevalence of mixed</bold></th><th><bold>Neuropsychology</bold></th><th><bold>Interaction between VBI and AD on risk of dementia</bold></th></tr></thead><tbody><tr valign='top'><td rowspan='5'>Subcortical Ischemic Vascular Dementia (SIVD) study [<xref rid='CR18' ref-type='bibr'>18</xref>]</td><td>N = 61</td><td rowspan='5' align='left'>78 (at time of neuropsych)</td><td>CERAD</td><td>CVD-PS</td><td rowspan='5'></td><td rowspan='2'>Linear composite measures</td><td rowspan='5'>AD patient scores were lower than EXEC by nearly a standard deviation on average. VBI patients were rather equally impaired on EXEC,MEM and NVMEM</td></tr><tr valign='top'><td>AD = 23</td><td rowspan='4'>Braak and Braak ≥ IV</td><td rowspan='4'>Infarct score ≥20</td></tr><tr valign='top'><td>VBI = 11</td><td>GLOB</td></tr><tr valign='top'><td>Mixed = 9</td><td>MEM</td></tr><tr valign='top'><td>NSP = 19</td><td>EXEC</td></tr><tr valign='top'><td rowspan='5'>SIVD study [<xref rid='CR19' ref-type='bibr'>19</xref>]</td><td>N = 79</td><td align='left'>82.8 ± 7.0</td><td rowspan='2'>NINDS-ADRDA criteria</td><td rowspan='2'>ADDTC criteria</td><td rowspan='2'>Clin Dx = 28%</td><td rowspan='2'></td><td rowspan='2'>Positive likelihood ratios: AD = 6.4 &gt; VCI = 3.7 &gt; mixed = 2.3</td></tr><tr valign='top'><td>AD = 34</td><td rowspan='4'>At time of death</td></tr><tr valign='top'><td>VBI = 15</td><td>CERAD</td><td>CVD-PS</td><td rowspan='3'>Path Dx = 11%</td><td rowspan='3'>Cognitive status (CN, CIND, Dem)</td><td rowspan='3'>AD pathology and hippocampal sclerosis have relatively greater effect on cognition than VBI</td></tr><tr valign='top'><td>Mix = 9</td><td rowspan='2'>Braak and Braak ≥ IV</td><td rowspan='2'>Infarct score ≥20</td></tr><tr valign='top'><td>NSP = 21</td></tr><tr valign='top'><td rowspan='6'>SIVD study [<xref rid='CR20' ref-type='bibr'>20</xref>]</td><td>N = 93</td><td rowspan='6' align='left'>84</td><td colspan='5'>Lacunes associated with WMH</td></tr><tr valign='top'><td>Normal = 12</td><td colspan='5'>AD, atherosclerosis, and VBI contribute independently to cortical gray matter atrophy</td></tr><tr valign='top'><td>AD = 46</td><td colspan='5' rowspan='4'>AD and hippocampal sclerosis are associated with hippocampal atrophy</td></tr><tr valign='top'><td>VBI = 14</td></tr><tr valign='top'><td>Mixed = 9</td></tr><tr valign='top'><td>NSP = 12</td></tr><tr valign='top'><td rowspan='6'>SIVD study [<xref rid='CR21' ref-type='bibr'>21</xref>]</td><td>N = 163</td><td rowspan='6' align='left'>84</td><td colspan='5' rowspan='2'>Cerebral atherosclerosis was positively associated with microinfarcts (OR, 2.3; 95% CI, 1.2-4.4) and cystic infarcts (OR, 2.0; 95% CI, 1.0-4.2) but not AD pathology</td></tr><tr valign='top'><td>Normal = 23</td></tr><tr valign='top'><td>AD = 81</td><td colspan='5' rowspan='4'>Cerebral amyloid angiopathy was inversely associated with lacunar infarcts (OR, 0.6; 95% CI, 0.41-1.1), but positively associated with Braak and Braak stage (OR, 1.5; 95% CI, 1.1-2.1) and Consortium to Establish a Registry for Alzheimer Disease plaque score (OR, 1.5; 95% CI, 1.1-2.2)</td></tr><tr valign='top'><td>VBI = 21</td></tr><tr valign='top'><td>Mixed = 15</td></tr><tr valign='top'><td>NSP = 23</td></tr><tr valign='top'><td rowspan='6'>SIVD study (Zheng <italic>et al</italic>., manuscript submitted for publication)</td><td>N = 116</td><td rowspan='6' align='left'>84</td><td colspan='5' rowspan='6'>Pathological measures of AD, atherosclerosis, and VBI contribute independently to MRI cortical gray matter atrophy and cognitive impairment. Path analyses show that the adverse effects of atherosclerosis on cognition are largely mediated through subcortical infarcts to brain atrophy, while the effects of AD on cognition work equally through cortical atrophy as well as through a yet unmeasured direct pathway</td></tr><tr valign='top'><td>Normal = 12</td></tr><tr valign='top'><td>AD = 53</td></tr><tr valign='top'><td>VBI = 18</td></tr><tr valign='top'><td>Mixed = 9</td></tr><tr valign='top'><td>NSP = 24</td></tr></tbody></table><table-wrap-foot><p>AD, Alzheimer disease; ADDTC, Alzheimer’s Disease Diagnostic and Treatment Centers; CERAD, Consortium to Establish a Registry for Alzheimer Disease; CI, confidence interval; CIND, Cognitive impairment not meeting criteria for dementia; Clin Dx, clinical diagnosis; CN, cognitively normal; CVD-PS, cerebrovascular disease-parenchymal score; Dem, dementia; EXEC, executive score; GLOB, global cognition score; MEM, memory score; NINDS-ADRDA, National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; NSP, non-significant pathology; NVMEM, non-verbal memory; OR, odds ratio; Path Dx, pathological diagnosis; VBI, vascular brain injury; WMH, white matter hyperintensity.</p></table-wrap-foot></table-wrap></p><p><s sid='53'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The Rush Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP) constitute parallel, but independent, longitudinal clinical-pathological studies.</s><s sid='54'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Cases of clinically diagnosed probable AD often revealed a combination of AD plus other pathologies, especially VBI [<xref rid='CR8' ref-type='bibr'>8</xref>,<xref rid='CR22' ref-type='bibr'>22</xref>].</s><s sid='55'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the combined ROS and MAP autopsy samples (n = 804), mixed AD/VBI lesions were found in 16% of cases between ages 65 and 89 years, and grew to 28% after age 90 years [<xref rid='CR23' ref-type='bibr'>23</xref>].</s><s sid='56'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Among cases with dementia, the prevalence of mixed AD/VCI was higher in the community-based MAP cohort (44%) than in the religiously defined ROS cohort (28%) [<xref rid='CR8' ref-type='bibr'>8</xref>].</s><s sid='57'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The high prevalence of mixed AD/VBI and AD/VCI, especially in the oldest of old, underscores the importance of reducing VRFs as a public health priority.</s></p><p><s sid='58'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the Baltimore Longitudinal Aging Study (BLSA; n = 200), AD pathology alone accounted for 50% of the dementia seen in this cohort; hemispheral infarcts alone (VBI) or in conjunction with AD pathology (AD/VBI) accounted for 35%.</s><s sid='59'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In subjects with intermediate AD pathology scores, a single macroscopic hemispheral infarct was sufficient to cause dementia [<xref rid='CR10' ref-type='bibr'>10</xref>].</s><s sid='60'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Atherosclerosis, brain infarcts, and AD pathology all contributed independently to risk of dementia [<xref rid='CR11' ref-type='bibr'>11</xref>].</s><s sid='61'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Atherosclerosis scores were not correlated with AD pathology.</s></p><p><s sid='62'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the population-based Medical Research Council Cognitive Function and Ageing Study (CFAS; n = 456), the association between AD pathology (neuritic plaques and tangles) and cognitive status went down with age, while the association between atrophy and age continued to go up [<xref rid='CR12' ref-type='bibr'>12</xref>].</s><s sid='63'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Self-reported VRFs were associated with infarcts, but not AD pathology [<xref rid='CR13' ref-type='bibr'>13</xref>].</s><s sid='64'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Specifically, hypertension and heart attack were associated with microinfarcts in both dementia and non-dementia cases.</s><s sid='65'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the Cambridge City over-75 s cohort, 22% of 118 dementia cases were classified as mixed AD/VBI [<xref rid='CR14' ref-type='bibr'>14</xref>].</s></p><p><s sid='66'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the population-based Hisayama Study, among 275 cases of incident dementia followed to autopsy, 45% were classified as AD, 30% as VCI, 5% as mixed AD/VCI and 4% as dementia with Lewy bodies [<xref rid='CR15' ref-type='bibr'>15</xref>].</s><s sid='67'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The incidences of AD, combined dementia and other types of dementia rose with increasing age, particularly after the age of 85 years; this tendency was not observed for VCI or dementia with Lewy bodies.</s><s sid='68'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In an earlier autopsy study (n = 135), diabetes mellitus and insulin resistance were associated with neuritic plaques, but not neurofibrillary tangles [<xref rid='CR24' ref-type='bibr'>24</xref>].</s></p><p><s sid='69'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the Honolulu Asia Aging Study (HAAS) of older Japanese American men (n = 443 autopsies), microvascular lesions were the predominant lesion in 33% of dementia cases, AD the predominant lesion in 18.6% and mixed lesions (most often AD and VBI) in 14.2% [<xref rid='CR16' ref-type='bibr'>16</xref>].</s><s sid='70'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The frequency of AD pathology and brain atrophy increased steadily after age 72 years (12 to 35% and 25 to 63%, respectively), whereas the frequency of microvascular lesions remained fairly constant at around 30% across the older age spectrum.</s><s sid='71'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Lewy bodies and hippocampal sclerosis jumped up in frequency to 15% and 10%, respectively, after age 80 years.</s><s sid='72'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Hyp1' type='Hyp'></CoreSc1> The ratio of VBI to AD has been relatively higher in the HAAS cohort compared with other cohorts, raising the question of possible ethnic differences in gene-environment-brain interactions.</s></p><p><s sid='73'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Based on the above community and cohort studies of prevalence, we conclude that mixed AD/VBI ranks in the top three most prevalent pathologies (with AD and VCI), well ahead of dementia with Lewy bodies and hippocampal sclerosis.</s><s sid='74'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Several studies have noted that the prevalence of AD pathology and atrophy continue to grow with advancing age, while the prevalence of infarcts remains more constant across the younger, middle and oldest of old.</s><s sid='75'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The prevalence of VBI compared with AD is higher in studies of Japanese (Hisayama and HAAS) compared with studies of predominantly Caucasians in the United States and United Kingdom (ROS, MAP, BLSA, CFAS, Cambridge City over-75 s cohort).</s><s sid='76'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, among infarcts of various sizes, regardless of ethnicity, microinfarcts show the strongest correlation with cognitive impairment (HAAS, ROS, CFAS, BLSA).</s><s sid='77'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Consistently, autopsy studies have demonstrated that VBI and AD exert independent and additive effects on the risk of dementia.</s></p></sec><sec id='Sec3'><title>Weighting the relative effects of VBI, AD, and other pathological lesions on cognition</title><p><s sid='78'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Beyond knowing the relative prevalence of pathological lesions, it is essential to weight their importance for cognitive impairment.</s><s sid='79'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The two variables (prevalence and clinical relevance) are not necessarily correlated.</s><s sid='80'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the combined Rush ROS and MAP (n = 856) [<xref rid='CR25' ref-type='bibr'>25</xref>], subjects with normal cognition at enrollment who were followed longitudinally (mean 7.5 years) had a high prevalence of neuropathological findings at autopsy (mean age 88 years): 99% evinced plaques or tangles; 36% had at least one gross infarct; 28% had at least one microinfarct; and 11% had neocortical Lewy bodies.</s></p><p><s sid='81'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The relative weighting of these pathological lesions on longitudinal cognitive decline was also studied: 22% of the rate of decline was explained by global AD pathology, 6% by amyloid plaques, 34% by tangles, 2% by macroscopic infarcts, and 8% by neocortical Lewy bodies.</s><s sid='82'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> When analyzed in conjunction, all pathological indices explained 41% of the total variation in cognitive performance.</s><s sid='83'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In these two studies combined, the rank order significance of pathologic lesions for cognitive decline was: tangles &gt; Lewy bodies &gt; amyloid plaques &gt; macroscopic infarcts.</s></p><p><s sid='84'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The prevalence and impact of microinfarcts was examined in the ROS (n = 425 autopsies) [<xref rid='CR26' ref-type='bibr'>26</xref>].</s><s sid='85'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Microinfarcts were present in 36.5% of persons with dementia and 25.3% in persons without dementia.</s><s sid='86'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The presence of microinfarcts, especially in multiple cortical locations, increased the odds of dementia (odds ratio, 1.77; 95% confidence interval, 1.07 to 2.92) and lowered average global cognition (estimate, -0.287; standard error (SE), 0.113; <italic>P</italic> = 0.012).</s><s sid='87'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Microinfarcts were associated (in order of effect size) with lower perceptual speed (estimate, -0.400; SE, 0.117; <italic>P</italic> &lt; 0.001), semantic memory (estimate, -0.391; SE, 0.130; <italic>P</italic> = 0.003), and episodic memory (estimate, -0.279; SE, 0.138; <italic>P</italic> = 0.044).</s><s sid='88'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These associations were not modified by the presence of macroscopic infarcts or AD pathology, suggesting that the effects of microinfarcts were independent.</s><s sid='89'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Of relevance, 58 of 129 (45%) people with microinfarcts did not have macroscopic infarcts, reminding us that we cannot rely on MRI to exclude VBI.</s></p><p><s sid='90'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the HAAS, 65% of autopsied cases harbored microscopic brain infarcts (MBIs), which contributed significantly and independently to brain atrophy and cognitive impairment, particularly before dementia was clinically evident [<xref rid='CR17' ref-type='bibr'>17</xref>].</s><s sid='91'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Scalars were developed to represent the severity of five different pathologic lesions (AD, MBI, hippocampal sclerosis, Lewy bodies, and atrophy).</s><s sid='92'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Spearman rank correlations (r) between these scalars and the last Cognitive Abilities Screening Instrument score were all significant, as follows (in rank order): atrophy, r = -0.453; AD lesions, r = -0.299; hippocampal sclerosis, r = -0.200; MBI, r = -0.195; and Lewy bodies, r = -0.158 [<xref rid='CR27' ref-type='bibr'>27</xref>].</s><s sid='93'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The five types of pathology explained 40% of the variance in the last Cognitive Abilities Screening Instrument score [<xref rid='CR17' ref-type='bibr'>17</xref>].</s></p><p><s sid='94'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>In the Subcortical Ischemic Vascular Dementia study, a cohort was recruited from university-affiliated memory clinics, enriched for people who had lacunes and WMHs on MRI (Table <xref rid='Tab2' ref-type='table'>2</xref>).</s><s sid='95'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The correlation between level of cognitive impairment was far stronger with AD pathology and hippocampal sclerosis than VBI [<xref rid='CR19' ref-type='bibr'>19</xref>].</s><s sid='96'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The profile of cognitive impairment for neuropathologically defined mixed AD/subcortical vascular dementia (SVD) resembled that seen in AD cases (memory scores were lower than executive scores by nearly one standard deviation) rather than SVD (where all cognitive domains were impaired more or less equally) [<xref rid='CR18' ref-type='bibr'>18</xref>].</s><s sid='97'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These finding suggest that, in general, when SVD is combined with AD, the effects of AD on severity and profile of cognitive impairment overwhelm those contributed by SVD.</s></p><p><s sid='98'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Analyses of these longitudinal, clinical, neuropathological, and imaging studies have moved our understanding from prevalence to clinical relevance of various pathological hallmarks.</s><s sid='99'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These data confirm the malignancy of AD pathology and highlight the importance of microinfarcts as one form of VBI.</s><s sid='100'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> They demonstrate the usefulness of multivariate, continuous approaches to understanding brain-behavior relationships.</s><s sid='101'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> At the same time, they indicate the limitations of current neuroimaging and neuropathological measures to model and predict cognitive decline.</s></p></sec><sec id='Sec4'><title>Pathological correlates of structural MRI in mixed AD/VBI</title><p><s sid='102'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The advent of structural imaging computerized tomography (CT) scans in the 1970s and MRI scans in the 1980s) revolutionized our ability to visualize regional atrophy and large and small infarcts as well as WMHs and MBs [<xref rid='CR28' ref-type='bibr'>28</xref>].</s><s sid='103'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A few longitudinal studies have attempted to validate structural MRI measures (for example, atrophy, WMHs) in reference to neuropathologic lesions and cognitive impairment.</s><s sid='104'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Pointedly, however, MRI scans at 1.5 and 3 T are not able to visualize microinfarcts, a form of VBI with demonstrated relevance to cognitive impairment.</s><s sid='105'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recently, structural MRI at 7 T has revealed larger microinfarcts (for example, 0.7 mm diameter), whereas average microinfarcts (0.3 mm diameter) still fall below the detection threshold [<xref rid='CR29' ref-type='bibr'>29</xref>].</s></p><p><s sid='106'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>A variety of pathological changes in the brain parenchymal and vasculature have been ascribed to WMHs in late life (reviewed in [<xref rid='CR30' ref-type='bibr'>30</xref>]).</s><s sid='107'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Smooth, periventricular rims and punctuate lesions appear to have little clinical relevance.</s><s sid='108'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Irregular and confluent WMHs are correlated with a host of parenchymal changes (for example, variable loss of myelin and axons, and microglial and inflammatory changes) as well as a spectrum of vascular pathologies (for example, arteriolosclerosis, amyloid angiopathy, dilated perivascular spaces) [<xref rid='CR30' ref-type='bibr'>30</xref>].</s><s sid='109'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Deep WMH lesions are thought to result from chronic hypoperfusion and hypoxia in terminal vascular beds fed by long, penetrating arterioles [<xref rid='CR31' ref-type='bibr'>31</xref>] and/or from breakdown of the blood-brain barrier and activation of matrix metalloproteinases [<xref rid='CR32' ref-type='bibr'>32</xref>,<xref rid='CR33' ref-type='bibr'>33</xref>].</s><s sid='110'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the Oregon Brain Aging Study, arteriolosclerosis (as opposed to atherosclerosis) was found to be the strongest correlate of WMHs [<xref rid='CR34' ref-type='bibr'>34</xref>].</s></p><p><s sid='111'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In patients with AD, loss of fractional anisotropy, and increased mean and radial diffusivity are seen in white matter association tracts, especially the corpus callosum and cingulate and uncinate fasciculi [<xref rid='CR35' ref-type='bibr'>35</xref>,<xref rid='CR36' ref-type='bibr'>36</xref>].</s><s sid='112'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> These changes may be seen in the absence of WMHs, and most likely reflect secondary (Wallerian) degeneration from loss of cortical neurons/axons, but to some degree there is also a component of primary white matter degeneration [<xref rid='CR37' ref-type='bibr'>37</xref>].</s><s sid='113'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The co-occurrence of WMHs in AD is commonly associated with the ApoE ε4 genotype, CAA, or arteriolosclerosis [<xref rid='CR30' ref-type='bibr'>30</xref>,<xref rid='CR34' ref-type='bibr'>34</xref>].</s><s sid='114'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Thus, for the most part, WMHs in late life can be viewed as a marker for white matter change related to vasculopathy.</s></p><p><s sid='115'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>In the Subcortical Ischemic Vascular Dementia study, volumes of cortical gray matter, WMHs, hippocampus, and lacunes were obtained from structural MRI and correlated with pathology (Table <xref rid='Tab2' ref-type='table'>2</xref>).</s><s sid='116'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> WMHs were straightforwardly associated with pathologic measures of vascular white matter injury; discrete lesions &gt;3 mm and brighter than CSF correlated well with lacunar infarcts.</s><s sid='117'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> On the other hand, neuropathology correlations for hippocampal volume and cortical gray matter were more complex.</s><s sid='118'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Hippocampal sclerosis and AD pathology explained 33% of the variance in hippocampal volume.</s><s sid='119'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> A combination of AD pathology, arteriosclerosis, and subcortical VBI explained 25% of the variance in cortical gray matter [<xref rid='CR20' ref-type='bibr'>20</xref>].</s></p><p><s sid='120'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>To improve the clinical diagnosis of mixed AD/VBI, these findings suggest the requirement for a multi-variable and multi-modality algorithm.</s><s sid='121'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Structural MRI measures alone have limited sensitivity and specificity.</s><s sid='122'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> WMHs, infarcts, and hemorrhages on MRI may be taken as suitable markers for VBI (minus microinfarcts).</s></p><p><s sid='123'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>Hippocampal volume is a suitable marker for AD (but could also mean hippocampal sclerosis).</s><s sid='124'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> MRI atrophy, at least as a global measure, cannot be relied upon to differentiate a neurodegenerative versus vascular etiology.</s><s sid='125'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Several measures of amyloid and tau pathology (for example, amyloid and tau PET or CSF biomarkers) have been validated and would improve diagnostic specificity for AD.</s></p><sec id='Sec5'><title>Differentiation of mixed AD/VBI in the era of amyloid PET imaging</title><p><s sid='126'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1>Prior to the arrival of amyloid PET imaging [<xref rid='CR38' ref-type='bibr'>38</xref>] and the validation of CSF biomarkers [<xref rid='CR39' ref-type='bibr'>39</xref>], autopsy was essential to disclose the neuropathological hallmarks of AD (namely plaques and tangles).</s><s sid='127'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Hence our decision to begin a review of mixed AD/VCI with neuropathologically defined AD (Tables <xref rid='Tab1' ref-type='table'>1</xref> and <xref rid='Tab2' ref-type='table'>2</xref>).</s><s sid='128'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> During the past few years, however, the detection of early AD changes beginning in preclinical stages has been improved by amyloid PET ligands (for example, Pittsburgh Imaging Compound B (PiB), florbetapir, flutemetamole, and so on) [<xref rid='CR40' ref-type='bibr'>40</xref>,<xref rid='CR41' ref-type='bibr'>41</xref>].</s></p><p><s sid='129'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1>A team of investigators at Samsung Medical Center, Seoul, Korea, separated patients with severe WMHs (evidence of SVD) into two groups based on positive or negative retention of amyloid on PiB PET scans (Table <xref rid='Tab3' ref-type='table'>3</xref>).</s><s sid='130'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Mixed AD/SVD (31% of 45 patients) performed worse on delayed recall, had fewer lacunar infarcts and had greater hippocampal atrophy than pure SVD [<xref rid='CR42' ref-type='bibr'>42</xref>].</s><s sid='131'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The group went on to test the ability of MRI shape analysis to discriminate mixed AD/SVD from pure SVD [<xref rid='CR43' ref-type='bibr'>43</xref>].</s><s sid='132'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Among 68 patients with SVD defined by severe WMHs, 23 (33.8%) patients were defined as mixed AD/SVD based on positive PiB binding.</s><s sid='133'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> With use of hippocampal shape analysis alone, mixed SVD could be distinguished from pure SVD with 95.7% sensitivity and 68.9% specificity.</s><s sid='134'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> With use of amygdalar shape, the discrimination accuracy was 87.0% sensitivity and 68.9% specificity.</s><s sid='135'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The two groups could also be distinguished based on the shape of the hippocampus and amygdala.</s><table-wrap id='Tab3'><label>Table 3</label><caption><p><bold>Studies of mixed Alzheimer disease/vascular brain injury with Alzheimer disease defined by amyloid PET imaging</bold></p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th><bold>Study</bold></th><th><bold>N</bold></th><th><bold>Age (years)</bold></th><th><bold>AD = PiB+</bold></th><th><bold>VBI</bold></th><th><bold>Mixed AD/VBI</bold></th><th><bold>Mixed AD/VBI findings</bold></th></tr></thead><tbody><tr valign='top'><td rowspan='2'>Samsung [<xref rid='CR42' ref-type='bibr'>42</xref>]</td><td rowspan='2'>N = 45 SVD<break></break>severe WMH</td><td rowspan='2' align='left'>74.2 ± 7.6</td><td rowspan='2'></td><td>Pure SVD</td><td>Mixed AD/SVD</td><td rowspan='2'>Mixed AD/SVD performed worse on delayed recall, had fewer lacunar infarcts and had greater hippocampal atrophy than pure SVD.</td></tr><tr valign='top'><td>N = 31 (69%) PiB-</td><td>N = 14 (31%) PiB+</td></tr><tr valign='top'><td rowspan='4'>Samsung [<xref rid='CR43' ref-type='bibr'>43</xref>]</td><td rowspan='4'>N = 68 SVD</td><td rowspan='4'></td><td rowspan='4'></td><td>Pure SVD</td><td>Mixed AD/SVD</td><td>Differentiation of mixed AD/SVD from pure SVD:</td></tr><tr valign='top'><td>N = 45 (66.2%)</td><td>N = 23 (33.8%)</td><td rowspan='2'>Hippocampal shape analysis: 95.7% sensitivity; 68.9% specificity</td></tr><tr valign='top'><td rowspan='2'>PiB-</td><td rowspan='2'>PiB+</td></tr><tr valign='top'><td>Amygdalar shape analysis: 87.0% sensitivity; 68.9%</td></tr><tr valign='top'><td rowspan='4'>Aging Brain Study [<xref rid='CR44' ref-type='bibr'>44</xref>]</td><td rowspan='4'>N = 54</td><td rowspan='4' align='left'>79</td><td>PiB+</td><td>VBI: WMHs and infarcts</td><td rowspan='4'></td><td>No relationship between VBI (infarcts or WMHs) and PiB</td></tr><tr valign='top'><td></td><td></td><td>VBI is associated with impairment in EXEC</td></tr><tr valign='top'><td>N = 33 PiB-</td><td>N = 27 VBI-</td><td rowspan='2'>No relationship between PiB and cognition</td></tr><tr valign='top'><td>N = 21 PiB+</td><td>N = 27 VBI+</td></tr><tr valign='top'><td rowspan='3'>Aging Brain Study [<xref rid='CR45' ref-type='bibr'>45</xref>]</td><td rowspan='3'>N = 61</td><td rowspan='3' align='left'>79</td><td></td><td>VBI: Infarcts</td><td rowspan='3'></td><td rowspan='3'>Infarction, particularly in cortical and subcortical gray matter, was associated with lower cognitive performance in all domains (<italic>P</italic> &lt; 0.05 for all comparisons)</td></tr><tr valign='top'><td>N = 32 PiB-</td><td>N = 27 infarct-</td></tr><tr valign='top'><td>N = 29 PiB+</td><td>N = 34 infarct+</td></tr><tr valign='top'><td>Aging Brain Study [<xref rid='CR46' ref-type='bibr'>46</xref>]</td><td>N = 43</td><td align='left'>78.9 (6.7)</td><td colspan='4'>FCRP accounted for 16% of the variance in PiB index (<italic>P</italic> &lt; 0.008) and the positive association remained significant controlling for age and sex, and apolipoprotein E genotype</td></tr><tr valign='top'><td rowspan='4'>Aging Brain Study [<xref rid='CR47' ref-type='bibr'>47</xref>]</td><td>N = 74</td><td rowspan='4' align='left'>79</td><td colspan='4' rowspan='4'>Higher LDL-C and lower HDL-C levels were both associated with a higher PiB index, independent of apolipoprotein E genotype</td></tr><tr valign='top'><td align='left'>33 NCI</td></tr><tr valign='top'><td align='left'>38 MCI</td></tr><tr valign='top'><td align='left'>3 CDR1</td></tr><tr valign='top'><td rowspan='4'>Aging Brain Study [<xref rid='CR48' ref-type='bibr'>48</xref>]</td><td>N = 67</td><td rowspan='4' align='left'>79</td><td colspan='4'>A relationship between Aβ and memory was mediated by cortical thickness.</td></tr><tr valign='top'><td align='left'>35 NCI</td><td colspan='4' rowspan='2'>The relationship between Aβ and cortical thickness was eliminated after controlling for FCRP, except in PiB+ subjects (n = 22), where Aβ remained associated with thinner cortex in precuneus and occipital lobe</td></tr><tr valign='top'><td align='left'>31 MCI</td></tr><tr valign='top'><td align='left'>1 CDR1</td><td colspan='4'>Vascular risk and Aβ both contribute to cortical thickness</td></tr></tbody></table><table-wrap-foot><p>Aβ, amyloid-beta; AD, Alzheimer disease; CDR, Clinical Dementia Rating; EXEC, executive score; FCRP, Framingham Coronary Risk Profile; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein-cholesterol; MCI, mild cognitive impairment; NCI, no cognitive impairment; PET, positron emission tomography; PiB, Pittsburgh Imaging Compound B; SVD, subcortical vascular dementia; VBI, vascular brain injury; WMH, white matter hyperintensity.</p></table-wrap-foot></table-wrap></p><p><s sid='136'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the Aging Brain Study [<xref rid='CR44' ref-type='bibr'>44</xref>,<xref rid='CR45' ref-type='bibr'>45</xref>], a longitudinal cohort enriched for vascular disease, no associations were found between measures of VBI on MRI and amyloid retention on PiB PET (Table <xref rid='Tab3' ref-type='table'>3</xref>).</s><s sid='137'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Participants with infarcts showed lower executive functioning (<italic>P</italic> = 0.001).</s><s sid='138'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Subcortical infarcts were inversely associated with declines in executive and memory function, whereas cortical infarcts were mainly associated with decline in executive function.</s><s sid='139'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Global PiB retention was associated with diminished non-verbal memory.</s><s sid='140'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Within this spectrum of normal aging to mild dementia, VBI and Aβ aggregation appeared to be independent processes with VBI having a greater impact on cognition than PiB retention.</s><s sid='141'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These studies illustrate how amyloid PET imaging will greatly improve our ability to recognize mixed AD/VCI cases of dementia.</s></p></sec><sec id='Sec6'><title>Differentiation of mixed AD/VBI with CSF biomarkers</title><p><s sid='142'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>CSF biomarkers for Aβ42 and tau also provide molecular evidence for AD, but the findings are more difficult to interpret.</s><s sid='143'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In the Amsterdam Dementia Cohort, the presence of both MBs and WMHs was associated with lower CSF levels of Aβ42, while lacunar infarcts were associated with higher Aβ42 and lower tau (Table <xref rid='Tab4' ref-type='table'>4</xref>) [<xref rid='CR49' ref-type='bibr'>49</xref>].</s><s sid='144'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The investigators concluded that the data supported a direct relationship between SVD and AD pathology.</s><s sid='145'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, if type of SVD is considered (that is, atherosclerosis versus CAA), the direct relationship between MBs and WMHs and AD biomarkers might reflect underlying CAA and AD, driven in common by ApoE ε4 genotype.</s><table-wrap id='Tab4'><label>Table 4</label><caption><p><bold>Studies of mixed Alzheimer disease/vascular brain injury with Alzheimer disease defined by cerebrospinal fluid Aβ and phosphorylated tau</bold></p></caption><table rules='groups' frame='hsides'><thead><tr valign='top'><th><bold>Study</bold></th><th><bold>N</bold></th><th><bold>AD =</bold></th><th><bold>VCI/VBI</bold></th><th><bold>VBI and AD correlations</bold></th></tr></thead><tbody><tr valign='top'><td rowspan='4'>ADNI [<xref rid='CR50' ref-type='bibr'>50</xref>]</td><td align='left'>N = 819</td><td align='left'>NINDS-ADRDA</td><td>VRFs</td><td>VRFs were not associated with AD biomarkers</td></tr><tr valign='top'><td align='left'>229 NCI</td><td rowspan='3'></td><td rowspan='3'>WMH</td><td rowspan='3'>Increased time-varying WMHs were associated with faster decline in executive function and lower FDG uptake in NCI</td></tr><tr valign='top'><td align='left'>397 CI</td></tr><tr valign='top'><td align='left'>193 AD</td></tr><tr valign='top'><td rowspan='4'>Amsterdam Dementia Cohort [<xref rid='CR49' ref-type='bibr'>49</xref>]</td><td>N = 914</td><td rowspan='4' align='left'>NINDS-ADRDA</td><td rowspan='4'>VCI by NINDS-AIREN criteria</td><td rowspan='3'>The presence of both MBs and WMHs was associated with lower CSF levels of Aβ42, indicating a direct relationship between SVD and AD pathology (note: could SVD be CAA?)</td></tr><tr valign='top'><td align='left'>337 NCI</td></tr><tr valign='top'><td align='left'>547 AD</td></tr><tr valign='top'><td align='left'>30 VCI</td><td>The presence of lacunes was associated with higher Aβ42 in vascular dementia (standardized beta = 0.17, <italic>P</italic> = 0.07) and lower tau in AD (standardized beta = -0.07, <italic>P</italic> = 0.05) but there were no effects for Aβ42 or phosphorylated tau181 in AD (note: could SVD with lacunes be arteriolosclerosis?)</td></tr></tbody></table><table-wrap-foot><p>Aβ, amyloid-beta; AD, Alzheimer disease; ADNI, Alzheimer’s Disease Neuroimaging Initiative; CAA, cerebral amyloid angiopathy; CI, cognitively impaired; CSF, cerebrospinal fluid; FDG, [<sup>18</sup> F]fluorodeoxyglucose; MB, microbleed; NCI, no cognitive impairment; NINDS-ADRDA, National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; NINDS-AIREN, National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences; SVD, subcortical vascular dementia; VBI, vascular brain injury; VCI, vascular cognitive impairment; VRF, vascular risk factor; WMH, white matter hyperintensity.</p></table-wrap-foot></table-wrap></p><p><s sid='146'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>In the Alzheimer Disease Neuroimaging Initiative, VRFs were not associated with AD biomarkers (that is, CSF amyloid, [<sup>18</sup> F]fluorodeoxyglucose (FDG) PET uptake or MRI hippocampal atrophy).</s><s sid='147'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In normal controls, progressive increases in WMH over time were associated with greater decline in executive function and lower FDG PET uptake (Table <xref rid='Tab4' ref-type='table'>4</xref>) [<xref rid='CR50' ref-type='bibr'>50</xref>].</s><s sid='148'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> One should keep in mind that the Alzheimer Disease Neuroimaging Initiative is focused on AD not CVD.</s><s sid='149'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The Framingham Coronary Risk Profile scores for the cohort were relatively low, approximately 18% across normal cognition, mild cognitive impairment and AD groups.</s><s sid='150'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Nonetheless, no interactions were noted between VRFs and AD biomarkers.</s></p></sec></sec><sec id='Sec7'><title>Other possible pathophysiological interactions between VRFs, CVD, and AD pathology</title><p><s sid='151'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Converging evidence from epidemiologic [<xref rid='CR51' ref-type='bibr'>51</xref>-<xref rid='CR53' ref-type='bibr'>53</xref>], neuropathologic, amyloid PET, and CSF biomarker studies show that VBI and AD exert additive adverse effects on cognitive health (Figure <xref rid='Fig1' ref-type='fig'>1</xref>).</s><s sid='152'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Do VRFs and CVD merely increase the co-occurrence of two separate processes (that is, AD and silent/symptomatic VBI), which shifts the syndromal diagnosis of dementia and AD earlier (reviewed in [<xref rid='CR9' ref-type='bibr'>9</xref>,<xref rid='CR54' ref-type='bibr'>54</xref>])?</s><s sid='153'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Or do VRFs and CVD potentiate AD-specific pathophysiological pathways, such as amyloidopathy and tauopathy?</s><s sid='154'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Several mechanisms have been postulated by which Aβ may be cleared in the brain: 1) enzymatic degradation (for example, neprilysin, insulin degrading enzyme) by microglia and astrocytes; 2) active transport from brain to blood through an endothelial lipoprotein receptor-related protein-mediated process [<xref rid='CR55' ref-type='bibr'>55</xref>-<xref rid='CR57' ref-type='bibr'>57</xref>]; and 3) passive transport through a perivascular ‘lymphatic-like’ drainage system of the brain [<xref rid='CR58' ref-type='bibr'>58</xref>,<xref rid='CR59' ref-type='bibr'>59</xref>].</s><s sid='155'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Recently, associations between the accumulation of Aβ on PiB PET scans with serum cholesterol and aortic arterial stiffness have been described [<xref rid='CR46' ref-type='bibr'>46</xref>,<xref rid='CR47' ref-type='bibr'>47</xref>,<xref rid='CR60' ref-type='bibr'>60</xref>].</s><s sid='156'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> However, direct associations between Aβ clearance and levels of brain cholesterol or cerebral arteriolar/venous stiffness in human beings have yet to be shown.</s><s sid='157'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> Thus, interactions at the pathophysiological level between VRFs/CVD and AD pathology, while plausible, are still unresolved.</s></p></sec><sec id='Sec8'><title>Type of cerebrovascular disease matters for prevention and treatment</title><p><s sid='158'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>VCI and VBI refer to phenotypes rather than treatable etiologies.</s><s sid='159'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Mot1' type='Mot'></CoreSc1> It should be apparent that clinical diagnosis must go further to identify the underlying type of CVD.</s><s sid='160'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> While there are many possible types of CVD, the three major types are atherosclerosis, arteriolosclerosis, and CAA.</s><s sid='161'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Risk factors for atherosclerosis and arteriolosclerosis overlap considerably and include hypertension, diabetes mellitus, and hyperlipidemia, which are easily measured and effectively treated with medications and lifestyle modifications.</s></p><p><s sid='162'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The location of some, but not all, structural imaging features may help to distinguish underlying arteriolosclerosis from CAA.</s><s sid='163'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> WMHs are associated with both hypertensive arteriosclerosis and severe CAA, with evidence of a more posterior location favoring CAA [<xref rid='CR61' ref-type='bibr'>61</xref>,<xref rid='CR62' ref-type='bibr'>62</xref>].</s><s sid='164'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Lacunar infarcts are more likely to be associated with arteriolosclerosis than with CAA [<xref rid='CR21' ref-type='bibr'>21</xref>].</s><s sid='165'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> The regional distribution of MBs may help to differentiate SVD and CAA; the occurrence of MBs in deep gray nuclei suggests SVD, while MBs in lobar or cortical regions suggest CAA [<xref rid='CR63' ref-type='bibr'>63</xref>,<xref rid='CR64' ref-type='bibr'>64</xref>].</s><s sid='166'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Though promising, the sensitivity and specificity of categorizing strictly lobar as CAA, strictly deep as hypertensive vasculopathy, or both lobar and deep as coexisting CAA and hypertensive vasculopathy has not yet been studied [<xref rid='CR64' ref-type='bibr'>64</xref>].</s></p><p><s sid='167'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Evidence-based treatment recommendations for VCI have been recently reviewed [<xref rid='CR1' ref-type='bibr'>1</xref>].</s><s sid='168'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Also, based on comprehensive reviews of the literature, and assuming a causal relationship and intervention at an appropriate age to reduce the prevalence of each of seven risk factors by 10% per decade, it has been estimated that the prevalence of AD/dementia could be reduced by 8.3% worldwide by 2050 [<xref rid='CR53' ref-type='bibr'>53</xref>].</s><s sid='169'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> This would translate to 1.1 to 3 million AD/dementia cases worldwide and 184,000 to 492,000 cases in the USA [<xref rid='CR65' ref-type='bibr'>65</xref>].</s><s sid='170'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> These risk factors include five vascular risk factors (that is, midlife hypertension, diabetes mellitus, mid-life hyperlipidemia, smoking, sedentary life style), as well as depression and low educational attainment.</s><s sid='171'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Arguably the epidemiological diagnosis of AD may well include cases with subclinical VBI or mixed AD/VBI.</s><s sid='172'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Regardless of etiological label, assuming internal consistency in the definitions of risk factors and the diagnosis of dementia subtype, the epidemiological data present a valid and worthy public health objective, namely a 10% reduction in VRFs for 10 years for an 8% reduction in dementia.</s></p><p><s sid='173'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The major risk factor for CAA is the ApoE ε4 allele, which can be determined readily by genotyping, though is not yet recommended by best practice guidelines.</s><s sid='174'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Strategies to reduce risks related to the ApoE ε4 genotype have been explored in cultured neurons [<xref rid='CR66' ref-type='bibr'>66</xref>] and in animal models of AD [<xref rid='CR67' ref-type='bibr'>67</xref>].</s><s sid='175'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> Bexaratone reduces amyloid plaques in animals, but no clinical trials have been conducted in humans.</s></p></sec><sec sec-type='conclusions' id='Sec9'><title>Conclusion</title><p><s sid='176'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>The co-occurrence of AD and VBI in elderly persons is very common.</s><s sid='177'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> There is now a large body of evidence showing that AD and VBI lead in an additive and independent fashion to cognitive dysfunction.</s><s sid='178'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> In AD, there is a characteristic pattern of tau-related, neurofibrillary neurodegeneration spreading from the medial temporal lobe to other multi-modal association areas and a corresponding pattern of memory loss spreading to other cognitive domains.</s><s sid='179'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> By contrast, there is tremendous variation in the neuropsychological profile associated with VBI.</s><s sid='180'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> In the SVD subtype of VCI, executive dysfunction often equals or may exceed memory impairment, but depending on location all varieties of cognitive impairment may ensue.</s></p><p><s sid='181'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>WMHs, small and large infarcts and hemorrhages are visible on structural MRI and CT imaging and currently serve as the most reliable marker for VBI.</s><s sid='182'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1> However, microinfarcts, which have been most strongly related to cognitive impairment in neuropathology studies, continue to elude clinical detection.</s><s sid='183'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> The validation of amyloid PET imaging adds considerable specificity for the diagnosis of AD, beyond the long recognized atrophy of the hippocampus.</s><s sid='184'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> The addition of tau PET imaging is expected shortly.</s><s sid='185'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Global measures of atrophy on MRI are important markers of overall brain injury, but cannot be used reliably to determine etiology.</s></p><p><s sid='186'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Bac1' type='Bac'></CoreSc1>Longitudinal studies with repeat neuropsychological testing support multivariate approaches to model the effects of various types of pathology on dementia risk and cognitive decline.</s><s sid='187'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Once comparable measures of AD and VBI pathology are available from <italic>in vivo</italic> neuroimaging studies, we can anticipate that one day dichotomous classifications will be replaced by more sophisticated modeling.</s><s sid='188'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Met1' type='Met'></CoreSc1> Still, the best models available today predict less than half of the variance in cognitive performance.</s></p><p><s sid='189'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1>For prevention and treatment, it is important to bear in mind the type of CVD underlying VBI and VCI, as well as to consider that subclinical CVD and VBI may contribute additively to cognitive impairment in patients with AD.</s><s sid='190'><CoreSc1 novelty='None' atype='GSC' advantage='None' conceptID='Con1' type='Con'></CoreSc1> Epidemiological data suggest that attention to ‘life’s simple seven’, referring to seven health factors and lifestyle behaviors identified by the American Heart Association that include being physically active, eating foods low in cholesterol and saturated fats, monitoring high blood pressure and blood sugar, maintaining a healthy weight, controlling cholesterol, and avoiding tobacco smoking, can significantly reduce the risk of dementia.</s></p></sec><sec sec-type='box' id='Sec10'><title>Note</title><p>This article is part of a series on <italic>Cerebral multi-morbidity of the aging brain</italic> edited by Johannes Attems and Julie Schneider. Other articles in the series can be found at <ext-link ext-link-type='uri' xlink:href='http://alzres.com/series/cerebral_multimorbidity'>http://alzres.com/series/cerebral_multimorbidity</ext-link>.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>Aβ</term><def><p>Amyloid-beta</p></def></def-item><def-item><term>AD</term><def><p>Alzheimer disease</p></def></def-item><def-item><term>ApoE</term><def><p>Apolipoprotein E</p></def></def-item><def-item><term>BLSA</term><def><p>Baltimore Longitudinal Aging Study</p></def></def-item><def-item><term>CAA</term><def><p>Cerebral amyloid angiopathy</p></def></def-item><def-item><term>CFAS</term><def><p>Cognitive Function and Ageing Study</p></def></def-item><def-item><term>CSF</term><def><p>Cerebrospinal fluid</p></def></def-item><def-item><term>CT</term><def><p>Computerized tomography</p></def></def-item><def-item><term>CVD</term><def><p>Cerebrovascular disease</p></def></def-item><def-item><term>FDG</term><def><p>[<sup>18</sup> F]fluorodeoxyglucose</p></def></def-item><def-item><term>HAAS</term><def><p>Honolulu Asia Aging Study</p></def></def-item><def-item><term>MAP</term><def><p>Memory and Aging Project</p></def></def-item><def-item><term>MB</term><def><p>Microbleed</p></def></def-item><def-item><term>MBI</term><def><p>Microscopic brain infarct</p></def></def-item><def-item><term>MRI</term><def><p>Magnetic resonance imaging</p></def></def-item><def-item><term>PET</term><def><p>Positron emission tomography</p></def></def-item><def-item><term>PiB</term><def><p>Pittsburgh Imaging Compound B</p></def></def-item><def-item><term>ROS</term><def><p>Religious Orders Study</p></def></def-item><def-item><term>SE</term><def><p>Standard error</p></def></def-item><def-item><term>SVD</term><def><p>subcortical vascular dementia</p></def></def-item><def-item><term>VBI</term><def><p>Vascular brain injury</p></def></def-item><def-item><term>VCI</term><def><p>Vascular cognitive impairment</p></def></def-item><def-item><term>VRF</term><def><p>Vascular risk factor</p></def></def-item><def-item><term>WMH</term><def><p>White matter hyperintensity</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by the National Institute on Aging: 1P01AG12435, 1P50AG05142.</p></ack><ref-list id='Bib1'><title>References</title><ref id='CR1'><label>1.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gorelick</surname><given-names>PB</given-names></name><name><surname>Scuteri</surname><given-names>A</given-names></name><name><surname>Black</surname><given-names>SE</given-names></name><name><surname>Decarli</surname><given-names>C</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Iadecola</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>2672</fpage><lpage>713</lpage><pub-id pub-id-type='doi'>10.1161/STR.0b013e3182299496</pub-id><pub-id pub-id-type='pmid'>21778438</pub-id></element-citation></ref><ref id='CR2'><label>2.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Craft</surname><given-names>S</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><etal></etal></person-group><article-title>Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>280</fpage><lpage>92</lpage><pub-id pub-id-type='doi'>10.1016/j.jalz.2011.03.003</pub-id><pub-id pub-id-type='pmid'>21514248</pub-id></element-citation></ref><ref id='CR3'><label>3.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>DeKosky</surname><given-names>ST</given-names></name><name><surname>Dickson</surname><given-names>D</given-names></name><name><surname>Dubois</surname><given-names>B</given-names></name><name><surname>Feldman</surname><given-names>HH</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><etal></etal></person-group><article-title>The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>270</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1016/j.jalz.2011.03.008</pub-id><pub-id pub-id-type='pmid'>21514249</pub-id></element-citation></ref><ref id='CR4'><label>4.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>McKhann</surname><given-names>GM</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Chertkow</surname><given-names>H</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Kawas</surname><given-names>CH</given-names></name><etal></etal></person-group><article-title>The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease</article-title><source>Alzheimers Dement</source><year>2011</year><volume>7</volume><fpage>263</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1016/j.jalz.2011.03.005</pub-id><pub-id pub-id-type='pmid'>21514250</pub-id></element-citation></ref><ref id='CR5'><label>5.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tomlinson</surname><given-names>BE</given-names></name><name><surname>Blessed</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Observations on the brains of non-demented old people</article-title><source>J Neurol Sci</source><year>1968</year><volume>7</volume><fpage>331</fpage><lpage>56</lpage><pub-id pub-id-type='doi'>10.1016/0022-510X(68)90154-8</pub-id><pub-id pub-id-type='pmid'>5707082</pub-id></element-citation></ref><ref id='CR6'><label>6.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Tomlinson</surname><given-names>BE</given-names></name><name><surname>Blessed</surname><given-names>G</given-names></name><name><surname>Roth</surname><given-names>M</given-names></name></person-group><article-title>Observations on the brains of demented old people</article-title><source>J Neurol Sci</source><year>1970</year><volume>11</volume><fpage>205</fpage><lpage>42</lpage><pub-id pub-id-type='doi'>10.1016/0022-510X(70)90063-8</pub-id><pub-id pub-id-type='pmid'>5505685</pub-id></element-citation></ref><ref id='CR7'><label>7.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Snowdon</surname><given-names>DA</given-names></name><name><surname>Greiner</surname><given-names>LH</given-names></name><name><surname>Mortimer</surname><given-names>JA</given-names></name><name><surname>Riley</surname><given-names>KP</given-names></name><name><surname>Greiner</surname><given-names>PA</given-names></name><name><surname>Markesbery</surname><given-names>WR</given-names></name></person-group><article-title>Brain infarction and the clinical expression of Alzheimer disease: The Nun Study</article-title><source>JAMA</source><year>1997</year><volume>277</volume><fpage>813</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1001/jama.1997.03540340047031</pub-id><pub-id pub-id-type='pmid'>9052711</pub-id></element-citation></ref><ref id='CR8'><label>8.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Aggarwal</surname><given-names>NT</given-names></name><name><surname>Barnes</surname><given-names>L</given-names></name><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>The neuropathology of older persons with and without dementia from community versus clinic cohorts</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>18</volume><fpage>691</fpage><lpage>701</lpage><pub-id pub-id-type='pmid'>19749406</pub-id></element-citation></ref><ref id='CR9'><label>9.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Wilson</surname><given-names>RS</given-names></name><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Boyle</surname><given-names>PA</given-names></name><name><surname>de Toledo-Morrell</surname><given-names>L</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name></person-group><article-title>Selected findings from the Religious Orders Study and Rush Memory and Aging Project</article-title><source>J Alzheimers Dis</source><year>2013</year><volume>33</volume><fpage>S397</fpage><lpage>403</lpage><pub-id pub-id-type='pmid'>22647261</pub-id></element-citation></ref><ref id='CR10'><label>10.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Zonderman</surname><given-names>AB</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name><name><surname>Crain</surname><given-names>B</given-names></name><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>O’Brien</surname><given-names>RJ</given-names></name></person-group><article-title>Effect of infarcts on dementia in the Baltimore longitudinal study of aging</article-title><source>Ann Neurol</source><year>2008</year><volume>64</volume><fpage>168</fpage><lpage>76</lpage><pub-id pub-id-type='doi'>10.1002/ana.21413</pub-id><pub-id pub-id-type='pmid'>18496870</pub-id></element-citation></ref><ref id='CR11'><label>11.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Dolan</surname><given-names>H</given-names></name><name><surname>Crain</surname><given-names>B</given-names></name><name><surname>Troncoso</surname><given-names>J</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name><name><surname>Zonderman</surname><given-names>AB</given-names></name><name><surname>Obrien</surname><given-names>RJ</given-names></name></person-group><article-title>Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort</article-title><source>Ann Neurol</source><year>2010</year><volume>68</volume><fpage>231</fpage><lpage>40</lpage><pub-id pub-id-type='pmid'>20695015</pub-id></element-citation></ref><ref id='CR12'><label>12.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Savva</surname><given-names>GM</given-names></name><name><surname>Wharton</surname><given-names>SB</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Forster</surname><given-names>G</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>Age, neuropathology, and dementia</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>2302</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1056/NEJMoa0806142</pub-id><pub-id pub-id-type='pmid'>19474427</pub-id></element-citation></ref><ref id='CR13'><label>13.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Richardson</surname><given-names>K</given-names></name><name><surname>Stephan</surname><given-names>BC</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Esiri</surname><given-names>MM</given-names></name></person-group><article-title>The neuropathology of vascular disease in the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS)</article-title><source>Curr Alzheimer Res</source><year>2012</year><volume>9</volume><fpage>687</fpage><lpage>96</lpage><pub-id pub-id-type='doi'>10.2174/156720512801322654</pub-id><pub-id pub-id-type='pmid'>22471870</pub-id></element-citation></ref><ref id='CR14'><label>14.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Brayne</surname><given-names>C</given-names></name><name><surname>Richardson</surname><given-names>K</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Fleming</surname><given-names>J</given-names></name><name><surname>Hunter</surname><given-names>S</given-names></name><name><surname>Xuereb</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>Neuropathological correlates of dementia in over-80-year-old brain donors from the population-based Cambridge city over-75 s cohort (CC75C) study</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>18</volume><fpage>645</fpage><lpage>58</lpage><pub-id pub-id-type='pmid'>19661624</pub-id></element-citation></ref><ref id='CR15'><label>15.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Matsui</surname><given-names>Y</given-names></name><name><surname>Tanizaki</surname><given-names>Y</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Yonemoto</surname><given-names>K</given-names></name><name><surname>Doi</surname><given-names>Y</given-names></name><name><surname>Ninomiya</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2009</year><volume>80</volume><fpage>366</fpage><lpage>70</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.2008.155481</pub-id><pub-id pub-id-type='pmid'>18977814</pub-id></element-citation></ref><ref id='CR16'><label>16.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>White</surname><given-names>L</given-names></name></person-group><article-title>Brain lesions at autopsy in older Japanese-American men as related to cognitive impairment and dementia in the final years of life: a summary report from the Honolulu-Asia aging study</article-title><source>J Alzheimers Dis</source><year>2009</year><volume>18</volume><fpage>713</fpage><lpage>25</lpage><pub-id pub-id-type='pmid'>19661625</pub-id></element-citation></ref><ref id='CR17'><label>17.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Hughes</surname><given-names>TM</given-names></name><name><surname>White</surname><given-names>LR</given-names></name></person-group><article-title>Microinfarcts, brain atrophy, and cognitive function: the Honolulu Asia Aging Study Autopsy Study</article-title><source>Ann Neurol</source><year>2011</year><volume>70</volume><fpage>774</fpage><lpage>80</lpage><pub-id pub-id-type='doi'>10.1002/ana.22520</pub-id><pub-id pub-id-type='pmid'>22162060</pub-id></element-citation></ref><ref id='CR18'><label>18.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Reed</surname><given-names>BR</given-names></name><name><surname>Mungas</surname><given-names>DM</given-names></name><name><surname>Kramer</surname><given-names>JH</given-names></name><name><surname>Ellis</surname><given-names>W</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Zarow</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Profiles of neuropsychological impairment in autopsy-defined Alzheimer’s disease and cerebrovascular disease</article-title><source>Brain</source><year>2007</year><volume>130</volume><fpage>731</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1093/brain/awl385</pub-id><pub-id pub-id-type='pmid'>17267522</pub-id></element-citation></ref><ref id='CR19'><label>19.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Zarow</surname><given-names>C</given-names></name><name><surname>Mack</surname><given-names>WJ</given-names></name><name><surname>Ellis</surname><given-names>WG</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><etal></etal></person-group><article-title>Cognitive impact of subcortical vascular and Alzheimer’s disease pathology</article-title><source>Ann Neurol</source><year>2006</year><volume>60</volume><fpage>677</fpage><lpage>87</lpage><pub-id pub-id-type='doi'>10.1002/ana.21009</pub-id><pub-id pub-id-type='pmid'>17192928</pub-id></element-citation></ref><ref id='CR20'><label>20.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Harvey</surname><given-names>DJ</given-names></name><name><surname>Mack</surname><given-names>WJ</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><etal></etal></person-group><article-title>Neuropathological basis of magnetic resonance images in aging and dementia</article-title><source>Ann Neurol</source><year>2008</year><volume>63</volume><fpage>72</fpage><lpage>80</lpage><pub-id pub-id-type='doi'>10.1002/ana.21296</pub-id><pub-id pub-id-type='pmid'>18157909</pub-id></element-citation></ref><ref id='CR21'><label>21.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Mack</surname><given-names>WJ</given-names></name><name><surname>Zarow</surname><given-names>C</given-names></name><name><surname>Ellis</surname><given-names>WG</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name></person-group><article-title>Cerebral atherosclerosis is associated with cystic infarcts and microinfarcts but not Alzheimer pathologic changes</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>2835</fpage><lpage>41</lpage><pub-id pub-id-type='doi'>10.1161/STROKEAHA.113.001945</pub-id><pub-id pub-id-type='pmid'>23887837</pub-id></element-citation></ref><ref id='CR22'><label>22.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Schneider</surname><given-names>JA</given-names></name><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Bang</surname><given-names>W</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name></person-group><article-title>Mixed brain pathologies account for most dementia cases in community-dwelling older persons</article-title><source>Neurology</source><year>2007</year><volume>69</volume><fpage>2197</fpage><lpage>204</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000271090.28148.24</pub-id><pub-id pub-id-type='pmid'>17568013</pub-id></element-citation></ref><ref id='CR23'><label>23.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>James</surname><given-names>BD</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Boyle</surname><given-names>PA</given-names></name><name><surname>Leurgans</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name></person-group><article-title>Dementia from Alzheimer disease and mixed pathologies in the oldest old</article-title><source>JAMA</source><year>2012</year><volume>307</volume><fpage>1798</fpage><lpage>800</lpage><pub-id pub-id-type='doi'>10.1001/jama.2012.3556</pub-id><pub-id pub-id-type='pmid'>22550192</pub-id></element-citation></ref><ref id='CR24'><label>24.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Matsuzaki</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>K</given-names></name><name><surname>Tanizaki</surname><given-names>Y</given-names></name><name><surname>Hata</surname><given-names>J</given-names></name><name><surname>Fujimi</surname><given-names>K</given-names></name><name><surname>Matsui</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study</article-title><source>Neurology</source><year>2010</year><volume>75</volume><fpage>764</fpage><lpage>70</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e3181eee25f</pub-id><pub-id pub-id-type='pmid'>20739649</pub-id></element-citation></ref><ref id='CR25'><label>25.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Boyle</surname><given-names>PA</given-names></name><name><surname>Wilson</surname><given-names>RS</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Barr</surname><given-names>AM</given-names></name><name><surname>Honer</surname><given-names>WG</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name><etal></etal></person-group><article-title>Much of late life cognitive decline is not due to common neurodegenerative pathologies</article-title><source>Ann Neurol</source><year>2013</year><volume>74</volume><fpage>478</fpage><lpage>89</lpage><pub-id pub-id-type='pmid'>23798485</pub-id></element-citation></ref><ref id='CR26'><label>26.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Arvanitakis</surname><given-names>Z</given-names></name><name><surname>Leurgans</surname><given-names>SE</given-names></name><name><surname>Barnes</surname><given-names>LL</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Schneider</surname><given-names>JA</given-names></name></person-group><article-title>Microinfarct pathology, dementia, and cognitive systems</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>722</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1161/STROKEAHA.110.595082</pub-id><pub-id pub-id-type='pmid'>21212395</pub-id></element-citation></ref><ref id='CR27'><label>27.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>White</surname><given-names>L</given-names></name><name><surname>Small</surname><given-names>BJ</given-names></name><name><surname>Petrovitch</surname><given-names>H</given-names></name><name><surname>Ross</surname><given-names>GW</given-names></name><name><surname>Masaki</surname><given-names>K</given-names></name><name><surname>Abbott</surname><given-names>RD</given-names></name><etal></etal></person-group><article-title>Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study</article-title><source>J Geriatr Psychiatry Neurol</source><year>2005</year><volume>18</volume><fpage>224</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1177/0891988705281872</pub-id><pub-id pub-id-type='pmid'>16306244</pub-id></element-citation></ref><ref id='CR28'><label>28.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Patel</surname><given-names>B</given-names></name><name><surname>Markus</surname><given-names>HS</given-names></name></person-group><article-title>Magnetic resonance imaging in cerebral small vessel disease and its use as a surrogate disease marker</article-title><source>Int J Stroke</source><year>2011</year><volume>6</volume><fpage>47</fpage><lpage>59</lpage><pub-id pub-id-type='doi'>10.1111/j.1747-4949.2010.00552.x</pub-id><pub-id pub-id-type='pmid'>21205241</pub-id></element-citation></ref><ref id='CR29'><label>29.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>van Veluw</surname><given-names>SJ</given-names></name><name><surname>Zwanenburg</surname><given-names>JJ</given-names></name><name><surname>Engelen-Lee</surname><given-names>J</given-names></name><name><surname>Spliet</surname><given-names>WG</given-names></name><name><surname>Hendrikse</surname><given-names>J</given-names></name><name><surname>Luijten</surname><given-names>PR</given-names></name><etal></etal></person-group><article-title>In vivo detection of cerebral cortical microinfarcts with high-resolution 7 T MRI</article-title><source>J Cereb Blood Flow Metab</source><year>2013</year><volume>33</volume><fpage>322</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1038/jcbfm.2012.196</pub-id><pub-id pub-id-type='pmid'>23250109</pub-id></element-citation></ref><ref id='CR30'><label>30.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gouw</surname><given-names>AA</given-names></name><name><surname>Seewann</surname><given-names>A</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Rozemuller</surname><given-names>AM</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2011</year><volume>82</volume><fpage>126</fpage><lpage>35</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.2009.204685</pub-id><pub-id pub-id-type='pmid'>20935330</pub-id></element-citation></ref><ref id='CR31'><label>31.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Pantoni</surname><given-names>L</given-names></name><name><surname>Garcia</surname><given-names>JH</given-names></name></person-group><article-title>Pathogenesis of leukoaraiosis: a review</article-title><source>Stroke</source><year>1997</year><volume>28</volume><fpage>652</fpage><lpage>9</lpage><pub-id pub-id-type='doi'>10.1161/01.STR.28.3.652</pub-id><pub-id pub-id-type='pmid'>9056627</pub-id></element-citation></ref><ref id='CR32'><label>32.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Taheri</surname><given-names>S</given-names></name><name><surname>Gasparovic</surname><given-names>C</given-names></name><name><surname>Shah</surname><given-names>NJ</given-names></name><name><surname>Rosenberg</surname><given-names>GA</given-names></name></person-group><article-title>Quantitative measurement of blood-brain barrier permeability in human using dynamic contrast-enhanced MRI with fast T1 mapping</article-title><source>Magn Reson Med</source><year>2011</year><volume>65</volume><fpage>1036</fpage><lpage>42</lpage><pub-id pub-id-type='doi'>10.1002/mrm.22686</pub-id><pub-id pub-id-type='pmid'>21413067</pub-id></element-citation></ref><ref id='CR33'><label>33.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Rosenberg</surname><given-names>GA</given-names></name><name><surname>Bjerke</surname><given-names>M</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name></person-group><article-title>Multimodal markers of inflammation in the subcortical ischemic vascular disease type of vascular cognitive impairment</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>1531</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1161/STROKEAHA.113.004534</pub-id><pub-id pub-id-type='pmid'>24692476</pub-id></element-citation></ref><ref id='CR34'><label>34.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Erten-Lyons</surname><given-names>D</given-names></name><name><surname>Woltjer</surname><given-names>R</given-names></name><name><surname>Kaye</surname><given-names>J</given-names></name><name><surname>Mattek</surname><given-names>N</given-names></name><name><surname>Dodge</surname><given-names>HH</given-names></name><name><surname>Green</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Neuropathologic basis of white matter hyperintensity accumulation with advanced age</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>977</fpage><lpage>83</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e3182a43e45</pub-id><pub-id pub-id-type='pmid'>23935177</pub-id></element-citation></ref><ref id='CR35'><label>35.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Alves</surname><given-names>GS</given-names></name><name><surname>O’Dwyer</surname><given-names>L</given-names></name><name><surname>Jurcoane</surname><given-names>A</given-names></name><name><surname>Oertel-Knöchel</surname><given-names>V</given-names></name><name><surname>Knöchel</surname><given-names>C</given-names></name><name><surname>Prvulovic</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Different patterns of white matter degeneration using multiple diffusion indices and volumetric data in mild cognitive impairment and Alzheimer patients</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e52859</fpage><pub-id pub-id-type='doi'>10.1371/journal.pone.0052859</pub-id><pub-id pub-id-type='pmid'>23300797</pub-id></element-citation></ref><ref id='CR36'><label>36.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Amlien</surname><given-names>IK</given-names></name><name><surname>Fjell</surname><given-names>AM</given-names></name></person-group><article-title>Diffusion tensor imaging of white matter degeneration in Alzheimer’s disease and mild cognitive impairment</article-title><source>Neuroscience</source><year>2014</year><volume>276C</volume><fpage>206</fpage><lpage>15</lpage><pub-id pub-id-type='doi'>10.1016/j.neuroscience.2014.02.017</pub-id><pub-id pub-id-type='pmid'>24583036</pub-id></element-citation></ref><ref id='CR37'><label>37.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Bozzali</surname><given-names>M</given-names></name><name><surname>Falini</surname><given-names>A</given-names></name><name><surname>Franceschi</surname><given-names>M</given-names></name><name><surname>Cercignani</surname><given-names>M</given-names></name><name><surname>Zuffi</surname><given-names>M</given-names></name><name><surname>Scotti</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>White matter damage in Alzheimer’s disease assessed in vivo using diffusion tensor magnetic resonance imaging</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2002</year><volume>72</volume><fpage>742</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.1136/jnnp.72.6.742</pub-id><pub-id pub-id-type='pmid'>12023417</pub-id></element-citation></ref><ref id='CR38'><label>38.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Engler</surname><given-names>H</given-names></name><name><surname>Nordberg</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Blomqvist</surname><given-names>G</given-names></name><name><surname>Holt</surname><given-names>DP</given-names></name><etal></etal></person-group><article-title>Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>306</fpage><lpage>19</lpage><pub-id pub-id-type='doi'>10.1002/ana.20009</pub-id><pub-id pub-id-type='pmid'>14991808</pub-id></element-citation></ref><ref id='CR39'><label>39.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Jack</surname><given-names>CR</given-names><suffix>Jr</suffix></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><etal></etal></person-group><article-title>Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade</article-title><source>Lancet Neurol</source><year>2010</year><volume>9</volume><fpage>119</fpage><lpage>28</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(09)70299-6</pub-id><pub-id pub-id-type='pmid'>20083042</pub-id></element-citation></ref><ref id='CR40'><label>40.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kantarci</surname><given-names>K</given-names></name></person-group><article-title>Molecular Imaging of Alzheimer Disease Pathology</article-title><source>AJNR Am J Neuroradiol</source><year>2014</year><volume>35</volume><fpage>S12</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.3174/ajnr.A3847</pub-id><pub-id pub-id-type='pmid'>24503555</pub-id></element-citation></ref><ref id='CR41'><label>41.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Landau</surname><given-names>SM</given-names></name><name><surname>Thomas</surname><given-names>BA</given-names></name><name><surname>Thurfjell</surname><given-names>L</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Margolin</surname><given-names>R</given-names></name><name><surname>Mintun</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2014</year><volume>41</volume><fpage>1398</fpage><lpage>407</lpage><pub-id pub-id-type='doi'>10.1007/s00259-014-2753-3</pub-id><pub-id pub-id-type='pmid'>24647577</pub-id></element-citation></ref><ref id='CR42'><label>42.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Seo</surname><given-names>SW</given-names></name><name><surname>Park</surname><given-names>HK</given-names></name><name><surname>Oh</surname><given-names>SJ</given-names></name><etal></etal></person-group><article-title>Identification of pure subcortical vascular dementia using 11C-Pittsburgh compound B</article-title><source>Neurology</source><year>2011</year><volume>77</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e318221acee</pub-id><pub-id pub-id-type='pmid'>21593437</pub-id></element-citation></ref><ref id='CR43'><label>43.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>BS</given-names></name><name><surname>Yoon</surname><given-names>CW</given-names></name><name><surname>Noh</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Individual subject classification of mixed dementia from pure subcortical vascular dementia based on subcortical shape analysis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e75602</fpage><pub-id pub-id-type='doi'>10.1371/journal.pone.0075602</pub-id><pub-id pub-id-type='pmid'>24130724</pub-id></element-citation></ref><ref id='CR44'><label>44.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Marchant</surname><given-names>NL</given-names></name><name><surname>Reed</surname><given-names>BR</given-names></name><name><surname>DeCarli</surname><given-names>CS</given-names></name><name><surname>Madison</surname><given-names>CM</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><etal></etal></person-group><article-title>Cerebrovascular disease, beta-amyloid, and cognition in aging</article-title><source>Neurobiol Aging</source><year>2012</year><volume>33</volume><fpage>1006 e1025-1036</fpage><pub-id pub-id-type='doi'>10.1016/j.neurobiolaging.2011.10.001</pub-id><pub-id pub-id-type='pmid'>22048124</pub-id></element-citation></ref><ref id='CR45'><label>45.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Marchant</surname><given-names>NL</given-names></name><name><surname>Reed</surname><given-names>BR</given-names></name><name><surname>Sanossian</surname><given-names>N</given-names></name><name><surname>Madison</surname><given-names>CM</given-names></name><name><surname>Kriger</surname><given-names>S</given-names></name><name><surname>Dhada</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>The aging brain and cognition: contribution of vascular injury and abeta to mild cognitive dysfunction</article-title><source>JAMA Neurol</source><year>2013</year><volume>70</volume><fpage>488</fpage><lpage>95</lpage><pub-id pub-id-type='doi'>10.1001/2013.jamaneurol.405</pub-id><pub-id pub-id-type='pmid'>23400560</pub-id></element-citation></ref><ref id='CR46'><label>46.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Reed</surname><given-names>BR</given-names></name><name><surname>Marchant</surname><given-names>NL</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>DeCarli</surname><given-names>CC</given-names></name><name><surname>Mack</surname><given-names>W</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name></person-group><article-title>Coronary risk correlates with cerebral amyloid deposition</article-title><source>Neurobiol Aging</source><year>2012</year><volume>33</volume><fpage>1979</fpage><lpage>87</lpage><pub-id pub-id-type='doi'>10.1016/j.neurobiolaging.2011.10.002</pub-id><pub-id pub-id-type='pmid'>22078485</pub-id></element-citation></ref><ref id='CR47'><label>47.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Reed</surname><given-names>B</given-names></name><name><surname>Villeneuve</surname><given-names>S</given-names></name><name><surname>Mack</surname><given-names>W</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Jagust</surname><given-names>W</given-names></name></person-group><article-title>Associations between serum cholesterol levels and cerebral amyloidosis</article-title><source>JAMA Neurol</source><year>2014</year><volume>71</volume><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type='doi'>10.1001/jamaneurol.2013.5390</pub-id><pub-id pub-id-type='pmid'>24378418</pub-id></element-citation></ref><ref id='CR48'><label>48.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Villeneuve</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>BR</given-names></name><name><surname>Wirth</surname><given-names>M</given-names></name><name><surname>Haase</surname><given-names>CM</given-names></name><name><surname>Madison</surname><given-names>CM</given-names></name><name><surname>Ayakta</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>Cortical thickness mediates the effect of beta-amyloid on episodic memory</article-title><source>Neurology</source><year>2014</year><volume>82</volume><fpage>761</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0000000000000170</pub-id><pub-id pub-id-type='pmid'>24489134</pub-id></element-citation></ref><ref id='CR49'><label>49.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Kester</surname><given-names>MI</given-names></name><name><surname>Goos</surname><given-names>JD</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Benedictus</surname><given-names>MR</given-names></name><name><surname>Bouwman</surname><given-names>FH</given-names></name><name><surname>Wattjes</surname><given-names>MP</given-names></name><etal></etal></person-group><article-title>Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers</article-title><source>JAMA Neurol</source><year>2014</year><volume>71</volume><fpage>855</fpage><lpage>62</lpage><pub-id pub-id-type='doi'>10.1001/jamaneurol.2014.754</pub-id><pub-id pub-id-type='pmid'>24818585</pub-id></element-citation></ref><ref id='CR50'><label>50.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Lo</surname><given-names>RY</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><collab>Alzheimer’s Disease Neuroimaging I</collab></person-group><article-title>Vascular burden and Alzheimer disease pathologic progression</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>1349</fpage><lpage>55</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0b013e31826c1b9d</pub-id><pub-id pub-id-type='pmid'>22972646</pub-id></element-citation></ref><ref id='CR51'><label>51.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Luchsinger</surname><given-names>JA</given-names></name><name><surname>Reitz</surname><given-names>C</given-names></name><name><surname>Honig</surname><given-names>LS</given-names></name><name><surname>Tang</surname><given-names>MX</given-names></name><name><surname>Shea</surname><given-names>S</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name></person-group><article-title>Aggregation of vascular risk factors and risk of incident Alzheimer disease</article-title><source>Neurology</source><year>2005</year><volume>65</volume><fpage>545</fpage><lpage>51</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000172914.08967.dc</pub-id><pub-id pub-id-type='pmid'>16116114</pub-id></element-citation></ref><ref id='CR52'><label>52.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Meng</surname><given-names>XF</given-names></name><name><surname>Yu</surname><given-names>JT</given-names></name><name><surname>Wang</surname><given-names>HF</given-names></name><name><surname>Tan</surname><given-names>MS</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>CC</given-names></name><etal></etal></person-group><article-title>Midlife vascular risk factors and the risk of Alzheimer’s disease: a systematic review and meta-analysis</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>42</volume><fpage>1295</fpage><lpage>310</lpage><pub-id pub-id-type='pmid'>25024338</pub-id></element-citation></ref><ref id='CR53'><label>53.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Norton</surname><given-names>S</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><name><surname>Barnes</surname><given-names>DE</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name><name><surname>Brayne</surname><given-names>C</given-names></name></person-group><article-title>Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data</article-title><source>Lancet Neurol</source><year>2014</year><volume>13</volume><fpage>788</fpage><lpage>94</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(14)70136-X</pub-id><pub-id pub-id-type='pmid'>25030513</pub-id></element-citation></ref><ref id='CR54'><label>54.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Chui</surname><given-names>HC</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Reed</surname><given-names>BR</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Mack</surname><given-names>WJ</given-names></name></person-group><article-title>Vascular risk factors and Alzheimer’s disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review</article-title><source>Alzheimers Res Ther</source><year>2012</year><volume>3</volume><fpage>36</fpage><pub-id pub-id-type='doi'>10.1186/alzrt98</pub-id></element-citation></ref><ref id='CR55'><label>55.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name><name><surname>Bu</surname><given-names>G</given-names></name></person-group><article-title>Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease</article-title><source>Cold Spring Harb Perspect Med</source><year>2012</year><volume>2</volume><fpage>a006312</fpage><pub-id pub-id-type='pmid'>22393530</pub-id></element-citation></ref><ref id='CR56'><label>56.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><article-title>Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders</article-title><source>Nat Rev Neurosci</source><year>2011</year><volume>12</volume><fpage>723</fpage><lpage>38</lpage><pub-id pub-id-type='pmid'>22048062</pub-id></element-citation></ref><ref id='CR57'><label>57.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Zlokovic</surname><given-names>BV</given-names></name></person-group><article-title>Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease</article-title><source>JAMA Neurol</source><year>2013</year><volume>70</volume><fpage>440</fpage><lpage>4</lpage><pub-id pub-id-type='doi'>10.1001/jamaneurol.2013.2152</pub-id><pub-id pub-id-type='pmid'>23400708</pub-id></element-citation></ref><ref id='CR58'><label>58.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Weller</surname><given-names>RO</given-names></name><name><surname>Djuanda</surname><given-names>E</given-names></name><name><surname>Yow</surname><given-names>HY</given-names></name><name><surname>Carare</surname><given-names>RO</given-names></name></person-group><article-title>Lymphatic drainage of the brain and the pathophysiology of neurological disease</article-title><source>Acta Neuropathol</source><year>2009</year><volume>117</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type='doi'>10.1007/s00401-008-0457-0</pub-id><pub-id pub-id-type='pmid'>19002474</pub-id></element-citation></ref><ref id='CR59'><label>59.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>MJ</given-names></name><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Thiyagarajan</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Sleep drives metabolite clearance from the adult brain</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>373</fpage><lpage>7</lpage><pub-id pub-id-type='doi'>10.1126/science.1241224</pub-id><pub-id pub-id-type='pmid'>24136970</pub-id></element-citation></ref><ref id='CR60'><label>60.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Hughes</surname><given-names>TM</given-names></name><name><surname>Kuller</surname><given-names>LH</given-names></name><name><surname>Barinas-Mitchell</surname><given-names>EJ</given-names></name><name><surname>Mackey</surname><given-names>RH</given-names></name><name><surname>McDade</surname><given-names>EM</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><etal></etal></person-group><article-title>Pulse wave velocity is associated with beta-amyloid deposition in the brains of very elderly adults</article-title><source>Neurology</source><year>2013</year><volume>81</volume><fpage>1711</fpage><lpage>8</lpage><pub-id pub-id-type='doi'>10.1212/01.wnl.0000435301.64776.37</pub-id><pub-id pub-id-type='pmid'>24132374</pub-id></element-citation></ref><ref id='CR61'><label>61.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Gurol</surname><given-names>ME</given-names></name><name><surname>Viswanathan</surname><given-names>A</given-names></name><name><surname>Gidicsin</surname><given-names>C</given-names></name><name><surname>Hedden</surname><given-names>T</given-names></name><name><surname>Martinez-Ramirez</surname><given-names>S</given-names></name><name><surname>Dumas</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study</article-title><source>Ann Neurol</source><year>2013</year><volume>73</volume><fpage>529</fpage><lpage>36</lpage><pub-id pub-id-type='doi'>10.1002/ana.23830</pub-id><pub-id pub-id-type='pmid'>23424091</pub-id></element-citation></ref><ref id='CR62'><label>62.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Thanprasertsuk</surname><given-names>S</given-names></name><name><surname>Martinez-Ramirez</surname><given-names>S</given-names></name><name><surname>Pontes-Neto</surname><given-names>OM</given-names></name><name><surname>Ni</surname><given-names>J</given-names></name><name><surname>Ayres</surname><given-names>A</given-names></name><name><surname>Reed</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Posterior white matter disease distribution as a predictor of amyloid angiopathy</article-title><source>Neurology</source><year>2014</year><volume>83</volume><fpage>794</fpage><lpage>800</lpage><pub-id pub-id-type='doi'>10.1212/WNL.0000000000000732</pub-id><pub-id pub-id-type='pmid'>25063759</pub-id></element-citation></ref><ref id='CR63'><label>63.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Seo</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>GH</given-names></name><name><surname>Noh</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><etal></etal></person-group><article-title>Pathogenesis of cerebral microbleeds: in vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment</article-title><source>Ann Neurol</source><year>2013</year><volume>73</volume><fpage>584</fpage><lpage>93</lpage><pub-id pub-id-type='doi'>10.1002/ana.23845</pub-id><pub-id pub-id-type='pmid'>23495089</pub-id></element-citation></ref><ref id='CR64'><label>64.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Martinez-Ramirez</surname><given-names>S</given-names></name><name><surname>Greenberg</surname><given-names>SM</given-names></name><name><surname>Viswanathan</surname><given-names>A</given-names></name></person-group><article-title>Cerebral microbleeds: overview and implications in cognitive impairment</article-title><source>Alzheimers Res Ther</source><year>2014</year><volume>6</volume><fpage>33</fpage><pub-id pub-id-type='doi'>10.1186/alzrt263</pub-id><pub-id pub-id-type='pmid'>24987468</pub-id></element-citation></ref><ref id='CR65'><label>65.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Barnes</surname><given-names>DE</given-names></name><name><surname>Yaffe</surname><given-names>K</given-names></name></person-group><article-title>The projected effect of risk factor reduction on Alzheimer’s disease prevalence</article-title><source>Lancet Neurol</source><year>2011</year><volume>10</volume><fpage>819</fpage><lpage>28</lpage><pub-id pub-id-type='doi'>10.1016/S1474-4422(11)70072-2</pub-id><pub-id pub-id-type='pmid'>21775213</pub-id></element-citation></ref><ref id='CR66'><label>66.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Chen</surname><given-names>HK</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Meyer-Franke</surname><given-names>A</given-names></name><name><surname>Brodbeck</surname><given-names>J</given-names></name><name><surname>Miranda</surname><given-names>RD</given-names></name><name><surname>McGuire</surname><given-names>JG</given-names></name><etal></etal></person-group><article-title>Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><fpage>5253</fpage><lpage>66</lpage><pub-id pub-id-type='doi'>10.1074/jbc.M111.276162</pub-id><pub-id pub-id-type='pmid'>22158868</pub-id></element-citation></ref><ref id='CR67'><label>67.</label><element-citation publication-type='journal'><person-group person-group-type='author'><name><surname>Cramer</surname><given-names>PE</given-names></name><name><surname>Cirrito</surname><given-names>JR</given-names></name><name><surname>Wesson</surname><given-names>DW</given-names></name><name><surname>Lee</surname><given-names>CY</given-names></name><name><surname>Karlo</surname><given-names>JC</given-names></name><name><surname>Zinn</surname><given-names>AE</given-names></name><etal></etal></person-group><article-title>ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models</article-title><source>Science</source><year>2012</year><volume>335</volume><fpage>1503</fpage><lpage>6</lpage><pub-id pub-id-type='doi'>10.1126/science.1217697</pub-id><pub-id pub-id-type='pmid'>22323736</pub-id></element-citation></ref></ref-list></back></article></PAPER>